Responding to Payor Policy Changes That Impact Patients with Postparalytic Facial Palsy: Chemodenervation with Botulinum Toxin

Facial Plast Surg Aesthet Med. 2022 Sep-Oct;24(5):335-336. doi: 10.1089/fpsam.2021.0372. Epub 2022 Feb 1.
No abstract available

MeSH terms

  • Botulinum Toxins, Type A* / therapeutic use
  • Facial Paralysis* / drug therapy
  • Humans
  • Nerve Block*
  • Neuromuscular Agents* / therapeutic use
  • Policy

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A